Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

Investing.com -- 专注于阿尔茨海默病治疗的生物技术公司Cassava Sciences, Inc.披露，其用于研究simufilam这种实验性药物的三期临床试验ReThink-ALZ未能达到预期目标。

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

智通财经APP获悉，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。 该公司总裁兼首席执行官里克·巴里表示：“对于患有这种疾病的患者及其家属以及一直在寻找新治疗方案的医生来说， ...

Cassava Sciences 陷入困境的阿尔茨海默病候选药物 simufilam 的开发似乎终于走到了尽头。 11月25日，这家总部位于德克萨斯州奥斯汀的生物技术公司透露 ...

NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did ...

(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...